Stock listing
Stuttgart:4XC1 KalVista Pharmaceuticals, Inc. Aktie
German listing (Stuttgart) of KalVista Pharmaceuticals, Inc. · home listing NASDAQ:KALV
Follow KalVista Pharmaceuticals, Inc. into a list and get an email when it puts out news.

- Ticker
- Stuttgart:4XC1
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Stuttgart
- Currency
- EUR
What changed lately
Latest news release · Nov 12, 2026
KalVista, a Company of the Chiesi Group, Reinforces Its Commitment to the Hereditary Angioedema (HAE) Community with New Real-World and Clinical Research Presented at the ACAAI Annual Meeting
Latest deck · October 2026
2026 HAEi Regional Conference Americas
Conference · 11 slides
Latest news
KalVista Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 15 in the last 12 months · 164 in all · newest Nov 12, 2026 · oldest 2019
- Calls
- 2 calls with a replay · 2 with a transcript · latest Nov 11, 2025
- Decks
- 17 decks · latest October 2026
Where KalVista Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:KALV · Home listing | NASDAQ | United States | USD |
| gettex:4XC1 | gettex | Germany | EUR |
| LS Exchange:A2DG49 | LS Exchange | Germany | EUR |
| Tradegate:4XC1 | Tradegate | Germany | EUR |
| BOATS:KALV | BOATS | United States | USD |
| Lang & Schwarz:A2DG49 | Lang & Schwarz | Germany | EUR |
| Frankfurt:4XC1 | Frankfurt | Germany | EUR |
| Munich:4XC1 | Munich | Germany | EUR |
| Dusseldorf:4XC1 | Dusseldorf | Germany | EUR |
| Hamburg:4XC1 | Hamburg | Germany | EUR |
| Stuttgart:4XC1 · This page | Stuttgart | Germany | EUR |
Team and board
Officers
| Officer | Role |
|---|---|
| Bilal Arif | Chief Operating Officer |
| Jeb Ledell | Chief Operating Officer |
| Leah Monteiro | Senior Director, Corporate Communications & Investor Relations |
| Molly Cameron | Sr. Director, Corporate Communications |
| Ryan Baker | Head, Investor Relations |
| Jenn Snyder | Vice President, Corporate Affairs |
Board
| Director | Role |
|---|---|
| Bethany L. Sensenig | Director |
| Laurence Reid | Director |
Events
| Call | When | Status |
|---|---|---|
| KalVista Pharmaceuticals (NASDAQ:KALV) Q3 2025 Earnings Call | Tue, Nov 11, 2025 · 8:30 AM ET | Replay |
| KalVista Pharmaceuticals (NASDAQ:KALV) Q2 2025 Earnings Call | Thu, Sep 11, 2025 · 8:30 AM ET | Replay |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| 2026 HAEi Regional Conference Americas | Conference | 11 slides | October 2026 |
| Investor Presentation (January 2026) | Investor deck | 20 slides | Jan 8, 2026 |
| Q2 2025 Earnings Presentation | Earnings | 19 slides | Sep 11, 2025 |
| Corporate Update (July 2025) | Corporate update | 24 slides | Jul 7, 2025 |
| Technical Presentation (May 2025) | Technical | 11 slides | May 2025 |
| Technical Presentation (May 2025) | Technical | 11 slides | May 2025 |
| Bradykinin Symposium 2024 | Conference | 13 slides | September 2024 |
| Technical Presentation (September 2024) | Technical | 11 slides | September 2024 |
| Technical Presentation (May 2024) | Technical | 16 slides | May 31, 2024 |
| Investor Presentation (February 2024) | Investor deck | 32 slides | Feb 13, 2024 |
All 17 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (2024) | Technical | 11 slides | 2024 |
| Technical Presentation (2024) | Technical | 11 slides | 2024 |
| Technical Presentation (May 2023) | Technical | 13 slides | May 2023 |
| Technical Presentation (May 2023) | Technical | 14 slides | May 2023 |
| HAEi Global Leadership Workshop, Frankfurt, October 6-9, 2022 | Conference | 13 slides | October 2022 |
| EAACI 2022 | Conference | 12 slides | Jul 1, 2022 |
| Investor Presentation (July 2018) | Investor deck | 36 slides | Jul 31, 2018 |
Financings
| Raise | Date |
|---|---|
| Convertible notes Closed: US$144M raised Use of proceeds: Continue advancing the global launch strategy for EKTERLY and building long-term growth | Nov 10, 2025 |
| Convertible Senior Notes due 2031 Announced: US$110M Use of proceeds: Working capital and general corporate purposes, including the commercialization of EKTERLY; possibly investments in or acquisitions of other companies or products | Sep 24, 2025 |
Open Financings · Read by 6ix AI from the company's releases
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Rajeev M Shah Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past) | Director · Nov 21, 2016 – Oct 12, 2017 · Past |
| William C. Fairey Other companies: Ascendis Pharma A/S (Director · Since at least Mar 18, 2026); Rein Therapeutics, Inc. (Director · Since at least Oct 31, 2023); Mirum Pharmaceuticals, Inc. (Director · Since at least Aug 19, 2021); MyoKardia Inc (EVP, Chief Commercial Officer · Jan 28, 2019 – Nov 17, 2020 · Past); ChemoCentryx Inc. (Chief Operating Officer · Jan 3, 2018 – Jan 3, 2018 · Past) | Director · Since at least Apr 18, 2024 |
| Albert Cha Other companies: Ascendis Pharma A/S (Chairman · Since at least Mar 18, 2026); Biohaven Pharmaceutical Holding Co Ltd (Director · May 3, 2017 – May 1, 2018 · Past); Aclaris Therapeutics, Inc. (Director · Oct 6, 2015 – Jun 29, 2016 · Past); Sierra Oncology Inc (Director · Jul 15, 2015 – Jul 21, 2015 · Past) | Director · Mar 23, 2017 – Sep 26, 2023 · Past |
| Richard Aldrich Other companies: Concert Pharmaceuticals Inc (Director · Feb 12, 2014 – Mar 6, 2023 · Past); PTC Therapeutics, Inc. (Director · Mar 7, 2013 – Jun 8, 2015 · Past); Tempest Therapeutics, Inc. (Director · Jun 11, 2012 – Dec 7, 2018 · Past); Verastem, Inc. (Director · Jan 26, 2012 – Jun 10, 2014 · Past) | Director · Nov 21, 2016 – Oct 3, 2018 · Past |
| Bilal Arif Other companies: Sarepta Therapeutics, Inc. (Chief Tech Ops Officer · Since at least Dec 31, 2022) | Chief Operating Officer · Since at least Oct 6, 2025 |
| Brian J. G. Pereira Other companies: ProKidney Corp. (Director · Since at least May 30, 2024) | Director · Since at least Oct 3, 2024 |
| Nancy Stuart Other companies: Concert Pharmaceuticals Inc (Chief Operating Officer · Jan 6, 2023 – Mar 6, 2023 · Past) | Director · Since at least Oct 13, 2022 |
| Nicole Sweeny Other companies: Monopar Therapeutics Inc. (Board Member · Since at least Jun 22, 2026) | Chief Commercial Officer · Since at least Jun 18, 2025 |
| Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER, Director · Since at least Apr 16, 2026 |
| Bethany L. Sensenig | Director · Since at least Oct 2, 2025 |
All 21 people
| Person | Seat |
|---|---|
| Christopher Yea | CHIEF DEVELOPMENT OFFICER · Since at least May 17, 2025 |
| Edward W Unkart | Director · Since at least Mar 23, 2017 |
| Jeb Ledell | Chief Operating Officer · Since at least Dec 16, 2024 |
| Jenn Snyder | Vice President, Corporate Affairs · Since at least Feb 10, 2025 |
| Laurence Reid | Director · Since at least Nov 26, 2024 |
| Leah Monteiro | Senior Director, Corporate Communications & Investor Relations · Since at least Feb 3, 2026 |
| Michael David Smith | Senior VP, Development · Dec 16, 2020 – May 17, 2022 · Past |
| Molly Cameron | Sr. Director, Corporate Communications · Since at least Apr 8, 2026 |
| Paul K Audhya | CHIEF MEDICAL OFFICER · Since at least May 17, 2025 |
| Ryan Baker | Head, Investor Relations · Since at least Apr 29, 2026 |
| Thomas Andrew Crockett | CEO, Director · Jun 4, 2018 – Feb 17, 2024 · Past |
Log in to ask 6ix AI your own questions about KalVista Pharmaceuticals, Inc.